Early real-world implant experience with a helix-fixation ventricular leadless pacemaker

• Published in: Journal of interventional cardiac electrophysiology 2024-10, Vol.67 (7), p.1539-1545
• Main Authors: Nair, Devi G., Exner, Derek V., Reddy, Vivek Y., Badie, Nima, Ligon, David, Miller, Marc A., Lee, Bridget, Doty, Brandon, Thomaides, Athanasios, Eldadah, Zayd, Islam, Malick, Hadadi, Cyrus
• Format: Article
• Language: English
• Subjects: Adverse events; Aged; Cardiac Pacing, Artificial - methods; Cardiology; Chambers; Early experience; Equipment Design; Female; Fixation; Fluoroscopy; Heart; Humans; Implantation; Male; Mapping; Medical instruments; Medicine; Medicine & Public Health; Middle Aged; Pacemaker, Artificial; Pacemakers; Prosthesis Implantation - methods; Retrospective Studies; Transplants & implants; Treatment Outcome; Ventricle
• ISSN: 1572-8595; 1383-875X; 1572-8595
• DOI: 10.1007/s10840-024-01791-1

Background Roughly one in six patients receiving conventional transvenous pacemaker systems experience significant complications within 1 year of implant, mainly due to the transvenous lead and subcutaneous pocket. A new helix-fixation single-chamber ventricular leadless pacemaker (LP) system capable of pre-deployment exploratory electrical mapping is commercially available. Such an LP may mitigate complications while streamlining the implantation. In this study, the initial real-world implant experience of the helix-fixation LP was evaluated following its commercial release. Methods In patients indicated for single-chamber right ventricular pacing, helix-fixation Aveir VR LPs (Abbott, Abbott Park, IL) were implanted using the dedicated loading tool, introducer, and delivery catheter. Implant procedural characteristics, electrical parameters, and any 30-day procedure-related adverse events of consecutive implant attempts were retrospectively evaluated. Results A total of 167 patients with Class I indication for permanent pacing received implants in four North American centers (57% male, 70 years old). Pre-fixation electrical mapping of potential sites allowed repositioning to be avoided in 95.7% of patients. Median [interquartile range] LP procedure and fluoroscopy durations were 25.5 min [20.0, 35.0] and 5.7 min [4.0, 9.2], respectively. Pacing capture threshold, sensed R-wave amplitude, and impedance were 0.8 V [0.5, 1.3], 9.0 mV [6.0, 12.0], and 705 Ω [550, 910], respectively. Implantation was successful in 98.8% of patients, with 98.2% free from acute adverse events. Conclusions The initial, real-world experience of the helix-fixation ventricular leadless pacemaker demonstrated safe and efficient implantation with minimal repositioning, viable electrical metrics, and limited acute complications. Graphical abstract Helix-fixation single-chamber ventricular leadless pacemakers were implanted in 167 patients, with a median procedure time of 25.5 minutes, 98.8% implant success, and 98.2% freedom from acute adverse events.